Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.59 |
| ▸ | CNR1 | P21554 | 11/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927643 | 0.90 | CNR2 (0.63) | CNR2CNR1RORC | |
| SCHEMBL926763 | 0.88 | CNR2 (0.66) | CNR2CNR1RORC | |
| SCHEMBL926911 | 0.88 | CNR2 (0.47) | CNR2CNR1LMNAMAPT | |
| SCHEMBL926960 | 0.86 | CNR2 (0.45) | CNR2CNR1MAPT | |
| SCHEMBL929987 | 0.86 | CNR2 (0.46) | CNR2CNR1MAPT | |
| SCHEMBL928016 | 0.86 | CNR2 (0.46) | CNR2CNR1MAPT | |
| SCHEMBL927437 | 0.85 | CNR2 (0.45) | CNR2CNR1KIF11MAPT | |
| SCHEMBL928431 | 0.84 | CNR2 (0.53) | CNR2CNR1MAPT | |
| SCHEMBL927584 | 0.84 | CNR2 (0.52) | CNR2CNR1MAPT | |
| SCHEMBL927879 | 0.83 | CNR2 (0.43) | CNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | claimed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| US-8598224-B2 | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885LMNA 3666/4885 |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885LMNA 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.